# SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

> **NCT05286931** · NA · RECRUITING · sponsor: **University of Washington** · enrollment: 1800 (estimated)

## Conditions studied

- Neisseria Gonorrhoeae Infection

## Interventions

- **DRUG:** Ciprofloxacin 500 mg

## Key facts

- **NCT ID:** NCT05286931
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-03
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2022-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286931, "SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05286931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*